Takeda’s Ninlaro has watched from the sidelines as competing multiple myeloma drugs jumped into additional indications. But now it may finally be ready to do the same.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,